Does Adding Ipilimumab to Nivolumab Improve Cancer Outcomes?
Nivolumab alone may offer equivalent clinical outcomes and lower toxicity than nivolumab plus ipilimumab in many advanced cancers other than melanoma, a new meta-analysis suggests.
Medscape Medical News
source https://www.medscape.com/viewarticle/996546?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/996546?src=rss
Comments
Post a Comment